English, Article edition: Economic Evaluation of Norethisterone Acetate/Ethinylestradiol (FemHRT(R)) for Women with Menopausal Symptoms Douglas Coyle; Ann Cranney; Peter Tugwell

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/95077
Physical Description
  • article
Language
  • English

Edition details

Title
  • Economic Evaluation of Norethisterone Acetate/​Ethinylestradiol (FemHRT(R)) for Women with Menopausal Symptoms
Author
  • Douglas Coyle
  • Ann Cranney
  • Peter Tugwell
Physical Description
  • article
Notes
  • Introduction: The objective of this study was to assess the cost effectiveness of a continuous combined oral preparation of norethisterone (norethindrone) acetate and ethinylestradiol (NA/​EE) [FemHRT(R)] as both a first-line and second-line therapy for menopausal women. Perspective: Third-party payer. Methods: The cost effectiveness of NA/​EE was assessed as both a first- and second-line therapy in comparison with conjugated equine oestrogen 0.625mg and medroxyprogesterone acetate 2.5mg (CEE/​MPA) and no therapy. Analysis was conducted within a Markov model with states relating to the presence and absence of vaginal bleeding, menopausal symptoms and hip fracture. Analysis forecasted life expectancy, QALYs and lifetime costs for a 50-year-old menopausal woman. Compliance was modelled related to menopausal symptoms and vaginal bleeding. For the base-case analysis, it was assumed that compliant women would take therapy for up to 5 years. Sensitivity analysis assumed therapy was taken only for 1 year. Results: Compared with both CEE/​MPA and no therapy, NA/​EE led to an increase in both costs and QALYs, both as a first- and second-line therapy. For first-line therapy, the incremental cost per QALY gained for NA/​EE was $2200 Canadian dollars ($Can; 1999 values) [compared with no therapy] and was $Can20 Conclusions: NA/​EE is a cost-effective therapy for women with menopausal symptoms both as a first-line and second-line therapy.
  • Conjugated-estrogens/​medroxyprogesterone, Cost-effectiveness, Ethinylestradiol/​norethisterone, Hormonal-replacements, Menopausal-syndrome, Menopause, Pharmacoeconomics
  • RePEc:wkh:phecon:v:21:y:2003:i:9:p:661-669
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment